Quinoline RORγt Modulators for Th17 Pathway Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune-mediated inflammatory diseases, such as psoriasis and rheumatoid arthritis, often target broader pathways like IL-12 and IL-23, but specific modulation of RORγt activity to inhibit Th17 cells is sought to effectively manage these conditions.
Innovation Solution
Pharmaceutical compositions comprising substituted quinoline compounds that act as RORγt modulators, specifically designed to prevent, treat, or ameliorate RORγt-mediated inflammatory syndromes, disorders, or diseases by administering effective amounts of these compounds to subjects in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments target broader pathways like IL-12 and IL-23, then therapeutic coverage is wide, but specificity in modulating RORγt activity is reduced
Solution Approach 1:
The patent extracts and isolates the specific RORγt nuclear receptor target from the broader IL-12/IL-23 pathway. By designing compounds that specifically bind to and modulate RORγt activity, the invention separates this specific target modulation from the broader pathway inhibition achieved by current treatments, thereby achieving higher specificity without requiring complex multi-target mechanisms
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular structures (substituted quinoline, pyridine, pyrimidine, and related heterocyclic compounds) that are tailored to interact with the unique binding pocket of RORγt. This localized molecular design ensures selective binding to RORγt rather than other nuclear receptors or pathway components, achieving high specificity through precise local molecular interactions
2Reliability
If monoclonal antibodies are used to block IL-12 and IL-23, then Th17 pathway inhibition is achieved, but selectivity for RORγt modulation is limited
Solution Approach 1:
The patent substitutes the mechanical/biological mechanism of monoclonal antibody binding with a small molecule chemical compound mechanism. The substituted heterocyclic compounds achieve RORγt modulation through direct chemical interaction with the nuclear receptor's ligand-binding domain, replacing the need for large protein-based monoclonal antibodies. This substitution maintains therapeutic efficacy while improving selectivity and simplifying manufacturing
Solution Approach 2:
The invention utilizes parameter changes in molecular structure (varying substituents on quinoline, pyridine, pyrimidine cores) to optimize RORγt binding affinity and selectivity. By systematically modifying chemical parameters such as substituent types, positions, and configurations, the patent achieves high selectivity for RORγt while maintaining ease of manufacture through established organic synthesis methodologies
Data Source
AI summary
The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.